Wells Fargo analyst Derek Archila has maintained their bullish stance on ARGX stock, giving a Buy rating on April 23.
Derek Archila has given his Buy rating due to a combination of factors that highlight the potential for revenue growth at Argenx Se. The introduction of Vyvgart Hytrulo’s pre-filled syringe is expected to significantly impact the market, particularly in the treatment of Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The convenience of at-home administration is likely to increase the adoption of this treatment option, capturing a substantial market share and expanding the overall market.
Derek Archila’s rating is also influenced by the anticipated increase in treatment cycles for MG patients. The recent physician survey indicates a higher average number of treatment cycles than previously estimated, suggesting a growing acceptance and utilization of Vyvgart. This trend, coupled with the potential for upward pricing pressure as patients opt for more frequent dosing, supports the expectation of continued revenue growth for Argenx Se.
In another report released on April 23, TD Cowen also maintained a Buy rating on the stock with a $761.00 price target.